An observational study in COVID-19, sponsored by University of Bologna. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by University of Bologna · Observational
In response to the COVID-19 crisis, ISACS-TC has promoted a new registry of the existing and further centers of the same geographic areas to support clinical research to prevent, and treat the COVID-19 illness. These efforts are made possible by the generous contributions of clinical research volunteers in some of the countries participating to the prior acute coronary syndrome network.
To address existing gaps in knowledge on CVD among European countries at different income levels, a collaboration of outcomes-oriented researchers from the University of Bologna partnered with Central and East European (CEE) countries researchers to conduct the International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC) investigating underlying threats in patients' CVD health status (NCT01218776).
In response to the COVID-19 crisis, ISACS-TC has promoted a new registry of the existing and further centers of the same geographic areas to support clinical research to prevent, and treat the COVID-19 illness. These efforts are made possible by the generous contributions of clinical research volunteers in some of the countries participating to the prior acute coronary syndrome network.
Scientific and clinical evidence is evolving on the effects of COVID-19, which can affect multiple organ systems. As, so the COVID-19 pandemic underscores the urgent need for coordination, collaboration, and information-sharing among researchers worldwide. Researchers of many disciplines have, therefore, joined the ISACS-TC investigators to build a multi-disciplinary registry investigating the impact of COVID-19.
Projects should be mainly focused on topics related to:
The second issue relates to the long-term health consequences after COVID-19 infection. Early reports suggest residual effects of SARS-CoV-2 infection, such as fatigue, dyspnea, chest pain, cognitive disturbances, arthralgia, and decline in quality of life. However, the evidence is still scarce. Prior studies did not take into account the vast majority of patients with a mild course of the infection. As well, the definition of the post-acute COVID-19 timeline is evolving. Today we may summarize the post-acute COVID-19 syndrome into two categories:
One trained physician will critically review the patients' reported symptoms and will assess SARS-CoV-2 IgG at each visit. In addition, wherever needed, the investigators will investigate the daily living status of survivors of COVID-19 using telephone interview questionnaires including Activity Daily Living (ADL), Self-rating Depression Scale (SDS), and New York Heart Association (NYHA) functional class.
National Investigators:
Bosnia and Herzegovina: Local PI: Mirza Dilic (Clinical Center University of Sarajevo)
Croatia: Local PI: Davor Miličić (University Hospital Center Zagreb)
Other Investigators:
Italy: Local PI: Stefano Nava (University of Bologna)
Other Investigators:
Macedonia: Local PI: Sasko Kedev and Marija Vavlukis (University "Ss. Cyril and Methodius")
Other Investigators:
Serbia: Local PI: Marija Zdravkovic (Hospital Medical Center Bezanijska kosa, Belgrade), Zorana Vasiljevic (University of Belgrade)
Other Investigators:
Spain: Local PI: Teresa Padro (IR-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona)
Other Investigators:
United Kingdom: Local PI: Charalambos Antoniades (Oxford University)
Other Investigators:
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 268 across 3,208 observational studies indexed under COVID-19.
Browse COVID-19 studies →University of Bologna is the lead sponsor of 158 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Confirmed diagnosis of COVID-19 infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-interventional patient registry
Combination Product: Observational (registry)
Non-interventional patient registry
Combination Product: Observational (registry)
Non-interventional patient registry
Combination Product: Observational (registry)
Non-interventional patient registry
Combination Product: Observational (registry)
Non-interventional patient registry
Combination Product: Observational (registry)
Non-interventional patient registry
Combination Product: Observational (registry)
Non-interventional patient registry
Combination Product: Observational (registry)
Non-interventional patient registry
Combination Product: Observational (registry)
Non-interventional patient registry
Combination Product: Observational (registry)
Non-interventional patient registry
Combination Product: Observational (registry)
Observational (Patient Registry)
Death all cause
Occurrence of all cause death
Time frame: 30-day
Death all cause
Occurrence of all cause death
Time frame: 6 month
Death all cause
Occurrence of all cause death
Time frame: 12-month
Heart failure
Occurrence of heart failure or worsening of preexisting heart failure (According to the attending physician)
Time frame: 30 day, 6 -12 months
Worsening renal function
Occurrence of kidney disease or worsening of preexisting kidney failure (According to the attending physician)
Time frame: 30 day, 6 -12 months
Respiratory Insufficiency
Occurrence of respiratory insufficiency or worsening of preexisting respiratory insufficiency (According to the attending physician)
Time frame: 30 day, 6 -12 months
Pneumonia
Occurrence of pneumonia (According to the attending physician)
Time frame: 30 day, 6 -12 months
Sepsis
Occurrence of sepsis (According to the attending physician)
Time frame: 30 day, 6 -12 months
Systemic Inflammatory Response Syndrome (SIRS)
Occurrence of SIRS (According to the attending physician)
Time frame: 30 day, 6 -12 months
Thrombosis (arterial, venous)
Occurrence of thrombosis and thromboembolism (According to the attending physician)
Time frame: 30 day, 6 -12 months
Clinically relevant bleeding
Occurrence of clinically relevant bleeding (According to the attending physician)
Time frame: 30 day, 6 -12 months
Activity Daily Living status
(According to the attending physician)
Time frame: 30 day, 6 -12 months
Depression status
(According to the attending physician)
Time frame: 30 day, 6 -12 months
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.